Abstract
Normal aerobic metabolism is associated with reactive oxygen species (ROS) that can damage cellular macromolecules. Analogous free radicals are formed by exposure to ionizing radiation and many dietary products are considered to contain free radical generators. During the past 15 years epidemiological studies and animal experiments have identified bilirubin as a molecule at the crossroads of the protection of the body against ROS. The studies have focused on bilirubin as a biomarker of arterial disease. This review assesses the current state of evidence and sets the data in context. There is no definitive evidence from prospective studies of a causal protective effect from bilirubin in arterial disease or that various genetic polymorphisms, (particularly the 7/7 UGT1A1 repeat polymorphism) impacts coronary artery disease. There is no definitive evidence that high bilirubin levels confer protection against cancer. There is some preliminary evidence that bilirubin may have a protective effect in lung disease and stroke, but the reports have yet to be confirmed. The role of various genotypes of UGT1A1 and HMOX1, if any, in cancer is unclear.
Keywords: Bilirubin, arterial disease, cancer, stroke, reactive oxygen species, UGT1A1, HMOX1, genotypes, albumin, urobilinogens
Current Pharmaceutical Design
Title: Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Volume: 17 Issue: 33
Author(s): Lars H. Breimer and Dimitri P. Mikhailidis
Affiliation:
Keywords: Bilirubin, arterial disease, cancer, stroke, reactive oxygen species, UGT1A1, HMOX1, genotypes, albumin, urobilinogens
Abstract: Normal aerobic metabolism is associated with reactive oxygen species (ROS) that can damage cellular macromolecules. Analogous free radicals are formed by exposure to ionizing radiation and many dietary products are considered to contain free radical generators. During the past 15 years epidemiological studies and animal experiments have identified bilirubin as a molecule at the crossroads of the protection of the body against ROS. The studies have focused on bilirubin as a biomarker of arterial disease. This review assesses the current state of evidence and sets the data in context. There is no definitive evidence from prospective studies of a causal protective effect from bilirubin in arterial disease or that various genetic polymorphisms, (particularly the 7/7 UGT1A1 repeat polymorphism) impacts coronary artery disease. There is no definitive evidence that high bilirubin levels confer protection against cancer. There is some preliminary evidence that bilirubin may have a protective effect in lung disease and stroke, but the reports have yet to be confirmed. The role of various genotypes of UGT1A1 and HMOX1, if any, in cancer is unclear.
Export Options
About this article
Cite this article as:
H. Breimer Lars and P. Mikhailidis Dimitri, Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220927
DOI https://dx.doi.org/10.2174/138161211798220927 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Inflammatory Effects of Fibrates: An Overview
Current Medicinal Chemistry Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews Advanced Glycation End Products (AGEs) and Cardiovascular Disease (CVD) in Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Designed Ankyrin Repeat Proteins: A Look at their Evolving Use in Medicine with a Focus on the Treatment of Chorioretinal Vascular Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Microvascular Endothelial Dysfunction in Obesity and Hypertension
Current Pharmaceutical Design The Role of Circadian Rhythms in Fatal Arrhythmias and the Potential Impact of Intervention for Sleep-Disordered Breathing
Current Pharmaceutical Design Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk
Current Vascular Pharmacology Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Biological Consequences of Dysfunctional HDL
Current Medicinal Chemistry Antibodies to Islet Beta Cell Surface Markers
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities
Mini-Reviews in Medicinal Chemistry Pharmacogenetics of Statins Therapy
Recent Patents on Cardiovascular Drug Discovery Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Acute Passivation of Vulnerable Plaques with Wild-Type Apolipoprotein A-I in ApoE-Deficient Mice
Vascular Disease Prevention (Discontinued) Regulatory Role of Brg1 and Brm in the Vasculature: From Organogenesis to Stress-Induced Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets The Potential of Statins for Individualized Colorectal Cancer Chemoprevention
Current Drug Targets Role of Inflammation in Diabetic Nephropathy
Current Diabetes Reviews Role of Focal Adhesion Kinase in Human Cancer: A Potential Target for Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry